ÅëÁõ °ü¸® ±â±â ½ÃÀåÀº 12.38%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·üÀ» ±â·ÏÇÒ Àü¸ÁÀ̸ç 2022³â 58¾ï 4,300¸¸ ´Þ·¯¿¡¼ 2029³â¿¡´Â 132¾ï 1,700¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸¸¼º Áúȯ Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡´Â ÅëÁõ °ü¸® ±â±â ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ÅëÁõ °ü¸®¿¡´Â ÀǾàǰ°ú ±â±â¸¦ Á¤È®ÇÏ°Ô Á¶ÇÕÇÏ¿© »ç¿ëÇÕ´Ï´Ù. ÅëÁõ °ü¸® ±â±â¿¡´Â °æÇÇ Àü±â ½Å°æ Æ®¸®°Å, ½Å°æ Æ®¸®°Å, ¹«Åë È¥ÇÕ ½ÃÆù, °íÁÖÆÄ ¾îºí·¹ÀÌÅÍ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±¸ÀÇ ´ëºÎºÐÀº ÅëÁõÀÇ ÀÔ±¸ ºÎºÐÀ» Â÷´ÜÇÏ¿© ÅëÁõÀÇ Â¡Èİ¡ ¸¶À½¿¡ ÀüÇØÁö´Â °ÍÀ» ¹æÁöÇÕ´Ï´Ù.
°íÁÖÆÄ ¾îºí·¹ÀÌÅÍ´Â ¿Â¿À» ¹ß»ý½ÃÄÑ ½Å°æÀ» ¼Ò¸ê½ÃÄÑ ÅëÁõ ½ÅÈ£¸¦ ¾ïÁ¦ÇÕ´Ï´Ù. À¯»çÇϰÔ, ½Å°æ Æ®¸®°Å ±â±â´Â °íÅë ½ÅÈ£ÀÇ Ä§ÀÔÀ» ¹æÇØÇϱâ À§ÇØ ¿ÂÈÇÑ Á֯ļöÀÇ Àü·ù¸¦ ÀÌ¿ëÇÕ´Ï´Ù. ÀÌ µµ±¸´Â ¾Ç¼º Á¾¾ç ¼ºÀå, ±Ù°ñ°Ý°è ¼Õ»ó, ½Å°æ º´Áõ ÅëÁõ°ú °°Àº µ¶Æ¯ÇÑ °íÅ뽺·¯¿î Áõ»óÀ» Ä¡·áÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÅëÁõ °ü¸® ±â±â´Â Àå½Ã°£ ÁøÁ¤Á¦, ºñ ½ºÅ×·ÎÀÌµå ¼º ÁøÁ¤Á¦ ¹× ±âŸ ÁøÅëÁ¦ÀÇ À§ÇùÀ» ÁÙÀ̱âÀ§ÇÑ Áö¿øÀ» Á¦°øÇÕ´Ï´Ù.
¹Ì±¹ Áúº´°ü¸®¿¹¹æ¼¾ÅÍ´Â ¹Ì±¹ ³» 5,000¸¸¸íÀÌ Áö¼ÓÀûÀÌ°í ¸¸¼ºÀûÀÎ ÀÏ»óÅë¿¡ °ßµð°í ÀÖ´Ù°í Æò°¡Çϸç, ±× Áß ¼ºÀÎ 1,960¸¸¸íÀº ÀÏ»ó»ýȰÀ̳ª Á÷¾÷¿¡ ÁöÀåÀ» ÁÖ´Â °Í°ú °°Àº ¿µÇâÀÇ Å« ¸¸¼ºÀûÀ̰í Áö¼ÓÀûÀÎ ÅëÁõÀÌ ÀÖ´Ù°íÇÕ´Ï´Ù. À̰ÍÀº ¿©·¯ ±¹°¡ÀÇ ÀÇ·á ºÎ´ãÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù.
ÅëÁõ °ü¸® ±â±â ½ÃÀåÀº ±â¼ú, ¿þ¾î·¯ºí ¹× °¡Á¦Æ®°¡ °í°´ÀÇ ÀÏ»ó »ýȰ¿¡ ³ì¾Æµé°í, ÀÌ·¯ÇÑ Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °ü½ÉÀÌ Âü½ÅÇÔ¿¡¼ ´õ ³Î¸® »ç¿ëµÇ´Â ÅëÁõ °ü¸® ±â¼ú·Î ÀüȯÇÔ¿¡ µû¶ó ¸Å·ÂÀûÀÔ´Ï´Ù.
ÀÇ·á½Ã¼³ÀÇ Ãæ½Ç°ú ÀüÀïÀÇ °¨¼Ò¿¡ ÀÇÇØ ¼¼°èÀûÀ¸·Î Àå¼öȰ¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¼ö¸íÀÌ ±æ¾îÁö¸é ÅëÁõÀÇ ¹ß»ý ºóµµµµ ³ô¾ÆÁö±â ¶§¹®¿¡ ÀÌ ºÒÄè°¨À» ¿¹¹æ ¹× °æ°¨ÇÒ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
65¼¼ ÀÌ»óÀÇ ³ëÀεé Áõ°¡´Â ÅëÁõ °ü¸® ±â±â ½ÃÀåÀÇ È®´ë¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°èÀºÇà¿¡ µû¸£¸é 2021³â¿¡´Â Àα¸ÀÇ 9.54%°¡ 65¼¼ ÀÌ»óÀÔ´Ï´Ù. ¶ÇÇÑ À¯¿£(UN) Åë°è 'World Population Prospects 2019'¿¡ µû¸£¸é ¼¼°è Àα¸´Â ÇâÈÄ 30³â°£ 2019³â 77¾ï ¸í¿¡¼ 2050³â 97¾ï ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, ¼¼°è ³ëÀÎ ÀÚ Àα¸µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼ ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¸¸¼º ¿äÅë°ú °üÀý¿°¿¡ ½Ã´Þ¸®°í ½ÃÀåÀÌ »ó½ÂÇϰԵ˴ϴÙ. ¿¹¸¦ µé¾î, 2023³â 12¿ù, SPR Therapeutics´Â ¸¸¼º ¿äÅë(LBP)¿¡ ´ëÇÑ SPRINT(R) PNS ½Ã½ºÅÛÀÇ RESET ÀÓ»ó½ÃÇè µî·ÏÀ» ¿Ï·áÇß½À´Ï´Ù. ÀÌ ¿¬±¸´Â ¸¸¼º ¿äÅë¿¡ ´ëÇÑ °æÇÇÀû ¸»ÃÊ ½Å°æ ÀÚ±Ø(PNS)°ú Ç¥ÁØ °³ÀÔ Ä¡·á¸¦ ºñ±³ÇÕ´Ï´Ù.
¿Ü°ú ¼ö¼ú ½Ç½Ã °Ç¼ö Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÕ´Ï´Ù.
ÅëÁõ °ü¸® ±â±â ½ÃÀåÀº ¼ö¼ú Áõ°¡¿¡ ÀÇÇØ Àü¹ÝÀûÀ¸·Î °ßÀεǰí ÀÖ½À´Ï´Ù. ¾ÏÀ̳ª ½Å°æ ¹®Á¦ µî Àå±âÀûÀÎ Áúº´ÀÇ ºñÀ²ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ¿Ü°ú ¼ö¼úÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ±× °á°ú ÅëÁõ ¿ÏÈ Çõ½ÅÀÇ Çʿ伺µµ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÅëÁõ°ü¸®±â±¸¿¡ ´ëÇÑ ¿ä±¸µµ ±â¼ú Çõ½ÅÀÇ ÁøÀü°ú °ÅÀÇ Ä§½ÀÀÌ ¾ø´Â ¹æ¹ýÀÇ µîÀå¿¡ ÀÇÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ Áúº´ÀÇ Á¶±â ¹ß°ß ¹× Á¶±âÄ¡·á¿¡ ´ëÇÑ ½ÅÈï±¹ ½ÃÀåÀÇ °³Ã´, ±¹¹ÎÀÇ ÇコÄÉ¾î °ü¸®¿¡ ´ëÇÑ ÀǽÄÀÇ ³ô¾ÆÁü, ÇコÄÉ¾î ¼ºñ½º¿¡ÀÇ ¾×¼¼½º Áõ°¡, ÇコÄÉ¾î °È¸¦ À§ÇÑ Á¤ºÎ ÇÁ·Î±×·¥ Áõ°¡ µîÀÌ ½ÃÀåÀ» °ßÀÎ ¿¹»óµË´Ï´Ù.
ÁøÅëÁ¦´Â ¼úÃë, Á¹À½, º¯ºñ, ¸Þ½º²¨¿ò µîÀÇ ºÎÀÛ¿ëÀÇ °¡´É¼ºÀÌ Àֱ⠶§¹®¿¡ Ä¡·áÀÇ Á¦ÀÏ ¼±ÅþàÀÌ µÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Áßµ¶¼º ¾à¹°Àº »óȲÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé ¼ö ÀÖ½À´Ï´Ù. ÅëÁõ °ü¸® ±â±â¿Í °°Àº ´ëü ÅëÁõ °ü¸® ¹æ¹ýÀº ¾à¹°À» »ç¿ëÇÏÁö ¾Ê°í ÅëÁõÀ» ¿ÏÈÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â±â´Â ¹°¸®Ä¡·á¿Í º´ÇàÇÏ¿© ¶Ç´Â ´Üµ¶ Ä¡·á·Î »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ºÎÀÛ¿ëÀ» ÁÙÀ̰í ÅëÁõ °ü¸®¸¦ °³¼±ÇÕ´Ï´Ù.
ºÏ¹Ì°¡ ½ÃÀå Á¡À¯À²À» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì°¡ ÅëÁõ°ü¸®±â±â ½ÃÀå¿¡¼ Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ´Â °ÍÀº ÇコÄÉ¾î ºÎ¹®ÀÇ È®´ë, ÇコÄɾÀÇ ÇöÀúÇÑ ÅõÀÚ, Çõ½ÅÀû ±â¼ú, ¸¸¼º ÅëÁõÀÇ ¹ß»ý·üÀÇ »ó½Â, ȯ°æ ±ÔÁ¦, Àü Áö¿ªÀÇ Çコ Äɾî ÇàÁ¤¿¡ÀÇ ¾×¼¼½ºÀÇ ¿ëÀÌÇÔ µîÀÌ ÀÌÀ¯ÀÔ´Ï´Ù. ¹Ì±¹Àº ¶ÇÇÑ ÀÇ·á ÀÎÇÁ¶ó°¡ ¼±ÁøÀûÀÌ¸ç ±â¼ú ¹ßÀü¿¡ ÁßÁ¡À» µÐ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2023³â 9¿ù ¹Ì±¹ ÀÇ·á±â±â Á¦Á¶¾÷üÀÎ º¸½ºÅÏ »çÀ̾ðƼÇÈ»ç´Â ¸¸¼º ¿äÅëÀÇ ÀÏÁ¾ÀÎ À̼Ҽº ÅëÁõÀ» Ä¡·áÇÏ´Â Intracept(R) Intraosseous Nerve Ablation SystemÀ» °³¹ß ¹× »óǰÈÇÑ ºñ »óÀåÀÇ ÀÇ·á ±â¼ú ±â¾÷ÀÎ Relievant Medsystems, Inc.¸¦ ÀμöÇÏ´Â °ÍÀ¸·Î ÇÕÀÇÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. º» °Å·¡¿¡´Â °è¾à ÀÏ½Ã±Ý 8¾ï 5,000¸¸ ´Þ·¯¿Í ÇâÈÄ 3³â°£ÀÇ ÆÇ¸Å ½ÇÀû¿¡ µû¸¥ Ãß°¡ÀûÀÎ ¼º°ø º¸»óÀÌ Æ÷ÇԵ˴ϴÙ. ÀÎÅͼÁÆ® ½Ã½ºÅÛÀº ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ Àΰ¡¸¦ ¹ÞÀº À¯ÀÏÇÑ À̼Ҽº ÅëÁõ Ä¡·á ½Ã½ºÅÛÀ¸·Î, Àúħ½ÀÀ¸·Î ÀÓÇöõÆ®¸¦ »ç¿ëÇÏÁö ¾Ê´Â ¿Ü·¡ ¼ö¼ú·Î, Ç¥ÀûÀ» Á¼Èù °íÁÖÆÄ ¿¡³ÊÁö¸¦ »ç¿ëÇÏ¿© ±â´ÉÀ» °³¼±Çϰí Àå±âÀûÀÎ ÅëÁõÀ» ¿ÏÈÇÕ´Ï´Ù.
³ëÀΰú »ýȰ ½À°üÀÇ Â÷ÀÌ·Î ÀÎÇÑ Áö¼ÓÀûÀÎ ÅëÁõÀÌ ¸¹¾ÆÁö¸é ºÏ¹Ì¿¡¼ ÅëÁõ Ä¡·á ±â±â ¼ö¿ä Áõ°¡¸¦ À̲ø¾î ³¾ ¼ö ÀÖ½À´Ï´Ù. ºÏ¹Ì, ƯÈ÷ ¹Ì±¹ÀÇ ±ÔÁ¦ ÀÌ´Ï¼ÅÆ¼ºê´Â ÅëÁõÀ» °ü¸®ÇÏ´Â ÀÇ·á±â±âÀÇ Áøº¸, ½ÂÀÎ ¹× »ó¾÷ȸ¦ Áö¿øÇÏ°í ±â¼ú Çõ½Å°ú È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ç° °ü¸® ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀº ÅëÁõ °ü¸® ±â±âÀÇ Ã¤Å÷ü Áõ°¡¿¡ ±â¿©ÇÕ´Ï´Ù.
The global pain management devices market is projected to witness a compounded annual growth rate of 12.38% to reach US$13.217 billion by 2029, up from US$5.843 billion in 2022.
Rising chronic diseases and the geriatric population are the key factors influencing the global pain management devices market. To manage pain, a precise combination of medicines or equipment is used. Pain management devices include transcutaneous electrical nerve triggers, neuro-triggers, the absence of pain mixture siphons, and radiofrequency ablators. A large portion of these devices blocks the pain entryway component to impede the section of pain signs to the mind.
Radiofrequency ablators obliterate nerves by creating warmth to impede the pain signals. Similarly, neuro-trigger devices utilize gentle frequencies of current to obstruct the entry of pain signals. These devices offer assistance in treating distinctive painful conditions like the growth of malignant, musculoskeletal damage, and neuropathic torment. Pain management instruments offer assistance to diminish the threat of long-haul sedatives, non-steroidal calming drugs, and other pain-mitigating medicines.
The Centers for Disease Control and Prevention evaluated that 50 million people within the US endure persistent and chronic daily pain, with adults accounting for 19.6 million that have high-impact chronic and unremitting pain that meddling with their capacity to live their day-to-day lives or their occupations. This is adding to the health care burden of several countries.
The market for pain management devices is appealing as technology, wearables, and gadgets become more integrated into customers' daily lives, and consumer interest in these products shifts from novelty to more widely used pain management techniques.
People are living longer than ever before worldwide owing to better healthcare facilities and fewer wars. Longer lifespans correspond to a higher occurrence of pain; thus, there is an increasing need to prevent and reduce this discomfort.
The rising number of individuals that over 65 is anticipated to contribute to the pain management devices market expansion. According to the World Bank, in 2021, 9.54% of the population was above 65 years of age. Further, as per the United Nations (UN) statistics for World Population Prospects 2019, the world population is anticipated to rise in the next 30 years, from 7.7 billion in the year 2019 to 9.7 billion in 2050, and the global elderly population is also rising. Thus, with rising elderly population suffers from chronic back pain and arthritis which will lead to a rise in the market. For instance, in December 2023, SPR Therapeutics completed enrollment in the RESET Clinical Trial of the SPRINT(R) PNS System for chronic low back pain (LBP), the largest prospective, multicenter randomized controlled trial to date. The trial compares percutaneous peripheral nerve stimulation (PNS) with standard interventional treatments for chronic LBP.
Increasing the number of surgical procedures carried out will bolster the market growth.
The market for pain management devices is being driven altogether by the rise in surgical operations. The rising rate of long-term sicknesses such as cancer and neurological issues has raised the requirement for surgical methods, which has, in turn, raised the requirement for pain alleviation innovation. The requirement for pain management instruments has also been extended by progresses in innovation and the appearance of negligibly intrusive methods.
Also, it is expected that the market will rise due to the developing accentuation on early illness discovery and treatment, rising awareness of healthcare management among the public, growing healthcare services access, and an increase in government programs to bolster healthcare, will drive the market.
Pain medications are frequently the primary line of treatment due to potential side effects such as sickness, drowsiness, constipation, and nausea. Addictive medications can further complicate the situation. Alternative pain management methods, such as pain management devices, can reduce pain without medication. These devices can be used alongside physical therapy or as standalone treatments, reducing side effects and improving pain management.
North America is expected to dominate the market share.
North America has a significant place in the pain management devices market due to its expansive healthcare sector, prominent investment in healthcare, innovative technology, rising chronic pain incidences, environment regulations, and accessibility to healthcare administrations for all regions. The US is also known for its progressed and advanced infrastructure of healthcare and accentuation on advancement in technology.
For instance, in September 2023, Boston Scientific, a US-based medical device manufacturer, announced an agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that developed and commercialized the Intracept(R) Intraosseous Nerve Ablation System for treating heterogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and additional contingent payments based on sales performance over the next three years. The Intercept system is the only U.S. Food and Drug Administration-cleared system for heterogenic pain, a minimally invasive, implant-free outpatient procedure that uses targeted radiofrequency energy to improve function and provide long-term relief.
The predominance of persistent pain due to an elderly populace and wrong lifestyle issues may drive the rising demand for pain administration devices in North America. The regulatory initiatives in North America, especially the US, assist the advancement, endorsement, and commercialization of medical devices that manage pain, cultivating innovation and expansion. This accessibility to healthcare services contributes to the higher adoption rate of pain management devices.